The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte-colony-stimulating factor-mobilized marrow harvests and peripheral blood harvests.
BACKGROUND
The association of donor characteristics with immune cell composition in allografts remains poorly understood. In this retrospective study, the effects of donor characteristics on immune cell composition in allografts were investigated.


METHODS
The correlations of donor characteristics with the immune cell composition in mixture allografts of granulocyte-colony-stimulating factor-mobilized marrow harvests and peripheral blood harvests of 390 healthy donors (male, 240; female, 150; median age, 40 years old) were analyzed.


RESULTS
The median doses of CD3+ T cells, CD4+ T cells, CD8+ T cells, CD3+CD4-CD8- T cells, and monocytes in mixture allografts were 160.57 × 10(6), 89.29 × 10(6), 56.16 × 10(6), 10.87 × 10(6), and 137.94 × 10(6)/kg, respectively. Multivariate analysis showed that younger donor age was associated with a higher dose of CD3+ T cells (p = 0.006), CD3+CD8+ T cells (p < 0.001), CD3+CD4-CD8- T cells (p = 0.004), and monocytes (p = 0.014), as well as a higher ratio of CD3+CD4-CD8- T cells/CD3+ T cells (p < 0.001) in the mixture allografts. A negative association of donor weight with CD3+ T cells (p < 0.001), CD4+ T cells (p = 0.002), CD8+ T cells (p < 0.001), and CD3+CD4-CD8- T cells (p = 0.044) was observed. The count of peripheral blood lymphocyte pre-peripheral blood apheresis was correlated with the yield of CD3+ T cells (p < 0.001) and CD4+ T cells (p = 0.001). The peripheral blood monocyte count before marrow harvest predicted the monocyte dose (p = 0.002).


CONCLUSIONS
The results suggested that older and overweight donors should not be chosen. The monocyte and lymphocyte counts before harvest could predict the yield of immune cells in allografts.
Peking University People's Hospital, Peking University Institute of Hematology.
Yu-Tong
YT
Wang
Peking University People's Hospital, Peking University Institute of Hematology.
Xiang-Yu
XY
Zhao
Peking University People's Hospital, Peking University Institute of Hematology.
Xiao-Su
XS
Zhao
Peking University People's Hospital, Peking University Institute of Hematology.
Lan-Ping
LP
Xu
Peking University People's Hospital, Peking University Institute of Hematology.
Xiao-Hui
XH
Zhang
Peking University People's Hospital, Peking University Institute of Hematology.
Yu
Y
Wang
Peking University People's Hospital, Peking University Institute of Hematology.
Kai-Yan
KY
Liu
Peking University People's Hospital, Peking University Institute of Hematology.|Collabrative Innovation Center of Hematology, Peking University.
Ying-Jun
YJ
Chang
Peking University People's Hospital, Peking University Institute of Hematology.|Collabrative Innovation Center of Hematology, Peking University.|Peking-Tsinghua Center for Life Sciences, Beijing, China.
Xiao-Jun
XJ
Huang
D000293:Adolescent; D000328:Adult; D000368:Aged; D064591:Allografts / Q000276:immunology*; D001854:Bone Marrow Cells / Q000276:immunology*; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014019:Tissue Donors
D016179:Granulocyte Colony-Stimulating Factor